# Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

> **NCT02843204** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fuda Cancer Hospital, Guangzhou** · enrollment: 110 (actual)

## Conditions studied

- Malignant Solid Tumour

## Interventions

- **DRUG:** Pembrolizumab
- **BIOLOGICAL:** NK immunotherapy

## Key facts

- **NCT ID:** NCT02843204
- **Lead sponsor:** Fuda Cancer Hospital, Guangzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-01
- **Primary completion:** 2017-07-01
- **Final completion:** 2019-07-01
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2020-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02843204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02843204, "Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02843204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*